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Abstract
Background: A greater reduction in cardiovascular risk and vascular protection associated with diet rich in polyphenols are
generally accepted; however, the molecular targets for polyphenols effects remain unknown. Meanwhile evidences in the
literature have enlightened, not only structural similarities between estrogens and polyphenols known as phytoestrogens,
but also in their vascular effects. We hypothesized that alpha isoform of estrogen receptor (ERa) could be involved in the
transduction of the vascular benefits of polyphenols.
Methodology/Principal Findings: Here, we used ERa deficient mice to show that endothelium-dependent vasorelaxation
induced either by red wine polyphenol extract, Provinols
TM, or delphinidin, an anthocyanin that possesses similar
pharmacological profile, is mediated by ERa. Indeed, Provinols
TM, delphinidin and ERa agonists, 17-beta-estradiol and PPT,
are able to induce endothelial vasodilatation in aorta from ERa Wild-Type but not from Knock-Out mice, by activation of
nitric oxide (NO) pathway in endothelial cells. Besides, silencing the effects of ERa completely prevented the effects of
Provinols
TM and delphinidin to activate NO pathway (Src, ERK 1/2, eNOS, caveolin-1) leading to NO production. Furthermore,
direct interaction between delphinidin and ERa activator site is demonstrated using both binding assay and docking. Most
interestingly, the ability of short term oral administration of Provinols
TM to decrease response to serotonin and to enhance
sensitivity of the endothelium-dependent relaxation to acetylcholine, associated with concomitant increased NO production
and decreased superoxide anions, was completely blunted in ERa deficient mice.
Conclusions/Significance: This study provides evidence that red wine polyphenols, especially delphinidin, exert their
endothelial benefits via ERa activation. It is a major breakthrough bringing new insights of the potential therapeutic of
polyphenols against cardiovascular pathologies.
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Introduction
Epidemiological studies have enlightened that women have lower
cardiovascular risk than men, and this protection progressively
disappears after menopause. These studies (protection in premeno-
pausal women) suggest and experimental studies (prevention of
atheroma development in animals) demonstrate a major atheropro-
tective action of 17-b-estradiol (E2)[ 1 , 2 ] .E 2 actions are essentially
mediated by two molecular targets: estrogen receptor alpha (ERa)
and beta (ERb), but theformer appearsto mediatemost of the actions
of E2 on the cardiovascular system [1,2]. Endothelium represents a
well recognized target of E2, which elicits several beneficial actions as
increased NO production [1–3] subsequent to activation of
endothelial NO synthase (eNOS) via a G-protein [4], and ERK
and phosphatidylinositol-3-kinase pathways.
Epidemiological studies reported a greater reduction in
cardiovascular risk and greater vascular protection associated with
diet rich in polyphenols, including those from red wine [5]. We
have previously shown that Provinols
TM, a polyphenolic extract
from red wine, and delphinidin, an anthocyanin pharmacologi-
cally active and found in the total extract, induce an increase of
endothelial NO production leading to endothelium-dependent
relaxation [6,7], even in pathophysiological contexts as hyperten-
sion, metabolic syndrome or stroke [8–10], and restore endothelial
function [11]. Although intracellular pathways involved in the
endothelial effects of polyphenols are partially described (increase
of intracellular calcium, activation of tyrosine kinases, for instance)
[7], the molecular targets of these polyphenols remain unknown. It
has to keep in mind that numerous molecules contained in red
wine polyphenols including resveratrol might act on synergistic
ways, in addition to their antioxidant properties, by acting as
agonists of sirtuin in order to increase life span and to silence
metabolic and physiological disturbances often associated with
endothelial NO dysfunction [12,13].
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similarities between estrogens and polyphenols known as phytoestro-
gens, but also in their vascular effects with regard to endothelial NO
production. Indeed, it has been reported that the phytoestrogen
genistein produces acute NO-dependent dilation of human forearm
vasculature with similar potency to E2 [14]. Also, genistein induces a
late but sustained activation of the eNOS system in vitro[15]. Moreover,
chronic administration of genistein improves endothelial dysfunction in
spontaneously hypertensive rats that involves eNOS, caveolin and
calmodulin expression and NADPH oxidase activity [16].
Red wine polyphenols do not contain genistein and no direct
evidence for the nature of the receptor triggering the effect of red
wine polyphenols receptors in endothelial cells has been
demonstrated. Nevertheless, the aim of this work was to investigate
the hypothesis that ERa is one of the targets involved in the
vasculoprotective effects of Provinols
TM and delphinidin. For this,
we first studied the endothelium-dependent relaxation to poly-
phenols in aortas from both ERa Knock-Out (KO) and Wild Type
(WT) mice, and then we analyzed molecular pathways associated
with NO production in endothelial cells stimulated by Provinols
TM
and delphinidin by silencing ERa activity or expression either with
pharmacological inhibitor or siRNA, respectively. We also studied
binding assay and molecular modelling of interaction between
delphinidin and ERa. Finally, we tested the physiological
relevance of our findings in vivo by testing the effect of short term
oral treatment of ERa KO and WT mice with Provinols
TM with
respect to endothelial NO response.
Results
The role of ERa in the endothelium-dependent relaxation to
Provinols
TM and to delphinidin was evaluated by using vessels
taken from ERa WT and KO mice. First, we tested the ability of
ERa agonists such as E2, which acts on both ERa and ERb
isoforms, and 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole
(PPT), which is specific for ERa, to activate the endothelium.
This was demonstrated by the capacity of the two ERa agonists to
induce relaxation in aortas from ERa WT but not from KO mice
in the presence of functional endothelium only (Figure 1A and 1B).
The concentration of E2 to elicit maximal relaxation was in
accordance with that reported by Li et al [17] in the same vessels.
As previously described by our group, red wine polyphenols and
delphinidin are able to induce endothelium-dependent relaxation
in mice aortas. Interestingly, the vasorelaxant effect of these two
polyphenols was found in aortas from ERa WT mice (Figure 1C
and 1D), but was completely abolished when ERa is deleted. In
ERa deficient mice, a slight contraction to Provinols
TM and
delphinidin were even detected (Figure 1C and 1D).
These data suggest the involvement of ERa in the endothelium-
dependent relaxation in response to the two polyphenols used.
Then, we assessed if the endothelium-dependent relaxation evoked
by ERa stimulation is due to an increase in NO production. For
this we stimulated the human endothelial cell line, EaHy 926,
either with Provinols
TM or delphinidin for 10 minutes in presence
or in absence of Fulvestrant, an ERa pharmacological antagonist,
or with a siRNA directed against ERa. Provinols
TM and
delphinidin were used at maximally active concentration to
induce relaxation in the rat aortic rings and to increase cytosolic
calcium in endothelial cells, as previously described [7,18]. Both
Provinols
TM and delphinidin were able to induce an increase in
NO production. However, when ERa was silenced either by
Fulvestrant or siRNA, the increase of NO production induced by
Provinols
TM and delphinidin was completely prevented
(Figure 2A). As a positive control for ERa activation-induced
Figure 1. ERa mediates endothelium-dependent relaxation induced by agonists, Provinols
TM and delphinidin. Concentration-effect
curves to increasing concentrations of PPT (A), 17-b estradiol (E2) (B), Provinols
TM (C) or delphinidin (D) in aortic rings, with functional endothelium
precontracted with U46619, taken from ERa Wild Type (open circles) and Knock-Out (filled circles) mice (n=5–6). **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0008554.g001
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enhance NO production, and this effect was abolished when ERa
was antagonized by Fulvestrant (Figure 2B). As EaHy 926 are
derived from human umbilical vein endothelial cells, we extracted
and cultured endothelial cells from aortas taken either from
ovariectomized ERa WT or KO mice, or from ovariectomized
Swiss mice, using the method described by Kobayashi et al. [19].
Cells were then stimulated with Provinols
TM, delphinidin and
PPT, in absence or in presence of Fulvestrant, using the same
protocol as for EaHy 926. Interestingly, in aortic endothelial cells
taken either from ERa WT mice or Swiss mice, Provinols
TM,
delphinidin and PPT were all able to induce NO production
(Figure 2C and 2E). The ability of the three compounds to
stimulate NO release was completely blunted in the aortic
endothelial cells extracted from ERa KO mice (Figure 2D) or in
aortic endothelial cells taken from ERa WT mice and Swiss mice
in the presence of Fulvestrant (Figure 2C and 2E).
Recently, an increase of NO production via the interaction of a
molecular pathway involving the phosphorylation of Src, ERK1/2
and eNOS on the Ser1177 has been reported with regard to
resveratrol [20]. NO pathway was then investigated in order to
decipher the molecular mechanisms underlying ERa-associated
NO increase and the subsequent vasodilatation induced either by
Provinols
TM, delphinidin or by PPT and E2. We also analysed
caveolin-1 expression, a protein that segregates the inactive form
of eNOS on the cellular membrane and modulates eNOS activity.
We demonstrated that both Provinols
TM and delphinidin
increased the phosphorylation of Src, ERK1/2 and eNOS Ser
1177, as well as of caveolin-1, in human endothelial cells.
Moreover, when ERa was blocked or silenced, the activation of
this pathway was completely blunted (Figure 3A to 3D). In
addition, the same effects were observed after PPT or E2 treatment
in the sense that the two ER agonists increased phosphorylation of
Src, ERK1/2, eNOS and caveolin-1. Furthermore, when ERa
was antagonized with Fulvestrant, neither PPT nor E2 induced
phosphorylation of these enzymes (Figure 3E to 3H), suggesting
the involvement of an ERa-dependent mechanism. Even if it has
already been shown that both Provinols
TM and delphinidin are
able to induce NO production in endothelial cells [18], and that
estrogens are also able to increase NO production via ERa [21],
here we demonstrate for the first time the direct link between the
ability of Provinols
TM and delphinidin to stimulate NO pathways
leading to endothelial NO production through ERa activation.
To verify the direct interaction of red wine polyphenols with
ERa and to exclude the implication of other factors, binding assay
between delphinidin and ERa was performed. Binding assay
showed that delphinidin exerts 73% of specific inhibition against
E2 on ERa (Figure 4D). Furthermore, we performed a docking
study of delphinidin on ERa. The predicted binding mode of the
ligand-binding domain on ERa is relatively similar to that
observed in the X-ray structure of the ERa with E2 (Figure 4A
and 4B). The three aromatic rings undergo significant apolar
contacts with hydrophobic residues located at the centre of the
binding site (Leu349, Ala350, Leu384, Leu387, Met388, Leu391,
Figure 2. ERa activation induces endothelial NO release. NO production induced by Provinols
TM, delphinidin, PPT and 17-b estradiol (E2)i n
endothelial cells and consequences of ERa pathway inhibition with either Fulvestrant or siRNA directed against ERa (siRNA). EaHy 926 cells (A and B)
or aortic endothelial cells from either ERa Wild-Type (WT) mice (C), ERa Knock-Out (KO) mice (D) or from Swiss mice (E) were treated for 10 minutes
with Provinols
TM (10
22 g/L), delphinidin (10
22 g/L), PPT (10
25 M) or E2 (10
25 M) and this in the presence or in the absence of either Fulvestrant
(30 nM) (hatched bars) or after knocking down the receptor with siRNA (siRNA) (striped bars). Then NO production was assessed by electronic
paramagnetic resonance. In panel A, insert shows Western blot for ERa in the control (lane 1) or ERa siRNA (lane 2)-treated Eahy endothelial cells.
*P,0.05, **P,0.01, ***P,0.001 vs non treated; #P,0.05, ##P,0.01 vs Provinols
TM, delphinidin (A, C and D), PPT or E2 alone (B and D), (n=4–6).
doi:10.1371/journal.pone.0008554.g002
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aromatic edge-to-face interaction is also engaged with the phenyl
ring of Phe404, as for E2. Last, a strong H-bond anchors
delphinidin and E2 to a polar residue (Glu353) at one end of the
binding site. A significant difference with the E2 binding mode is
the loss of two H-bonds to Arg394 and His524, which are partly
compensated by novel interactions to Leu346 (H-bond to the
backbone oxygen atom) and His524 (aromatic interaction). These
results indicate that delphinidin, like E2, interact directly with
ERa.
Finally, we show that short term oral administration of
Provinols
TM decreased contraction to serotonin (5-HT) in the
presence of functional endothelium (Figure 5A) and enhanced the
sensitivity to acetylcholine endothelium-dependent relaxation in
aorta from ERa WT mice (Figure 5C) in association with
increased NO production (Figure 5E) and reduced superoxide
anions in mesenteric arteries (Figure 5F). All of these effects of oral
administration of Provinols
TM were completely blunted in ERa
deficient mice (Figure 5B, 5D–5F). These results suggest that ERa
triggers the in vivo effects of Provinols
TM and demonstrate for the
first time the physiological relevance of this receptor.
Discussion
The present study identifies ERa as the, or at least one of, key
receptor transducing vascular effects exerted by red wine
polyphenols, particularly delphinidin with respect to NO produc-
tion. Indeed, E2 and PPT, as well as Provinols
TM and delphinidin,
are able to activate molecular pathways, involving Src, ERK1/2,
eNOS and caveolin-1 phosphorylations, by a mechanism that
required ERa activation, with subsequent increase of endothelial
NO production and endothelium-dependent vascular relaxation.
Moreover, using a binding assay and a docking, we showed that
delphinidin fits on ERa’s activation site. Most importantly,
evidence is provided that ERa triggers the in vivo effects of
Provinols
TM with respect to improvement in endothelial function
given by the concomitant increase in NO and decrease in O2
2
superoxide anions releases in vessels. The later demonstrate for the
first time the physiological relevance of this receptor in triggering
the vascular protection induced by red wine polyphenols.
Red wine contains a wide variety of polyphenols, which derive
mainly from grape solids (skin and seeds) and can be divided in
two classes, flavonoids and non-flavonoids. Although, the non-
flavonoid, resveratrol has been reported to trigger some of the
beneficial effects of red wine polyphenols including the activation
of sirtuin and NO pathway, we have focused our attention on the
flavonoid components of the red wine polyphenols such as
delphinidin. Indeed, our previous study looking at the possible
active principles that support the endothelial NO-dependent
relaxation produced by red wine polyphenols, including Provi-
nols
TM, demonstrate that anthocyanins and oligomeric-condensed
tannins exhibit a pharmacological profile comparable to the
original extract, the most potent being delphinidin [6]. Beside,
delphinidin has been reported to induce endothelial NO release via
an increase of cytosolic Ca
2+ in endothelial cells [7] and protects
against endothelial cell apoptosis acting through NO pathway
[22].
The major aim of this work was to investigate the hypothesis
that ERa is one of the targets involved in the vasculoprotective
effects of Provinols
TM and delphinidin. Firstly, we report the
existence of an endothelium-dependent relaxation associated with
ERa-stimulation, c-Src/ERK1/2-mediated activation of eNOS,
with consequent endothelial NO release via a non-genomic
mechanism at the same range of concentration than that reported
Figure 3. ERa activation induces phosphorylation of NO signaling proteins. Activation of NO pathway induced by Provinols
TM, delphinidin,
PPT and 17-b estradiol (E2) in endothelial cells and consequences of ERa pathway inhibition with either Fulvestrant or siRNA directed against ERa
(siRNA). EaHy 926 cells were treated for 10 minutes with Provinols
TM (10
22 g/L), delphinidin (10
22 g/L), PPT (10
25 M) or E2 (10
25 M) and this in the
presence or in the absence of either Fulvestrant (30 nM) (hatched bars) or after knocking down the receptor with siRNA (siRNA) (striped bars). Then
cells were lysed to perform Western Blot analysis. *P,0.05, **P,0.01, ***P,0.001 vs non treated; #P,0.05, ##P,0.01 vs Provinols
TM, delphinidin (A,
B, C and D), PPT or E2 alone (E, F, G and H), (n=4–6).
doi:10.1371/journal.pone.0008554.g003
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that the endothelium-dependent relaxation to Provinols
TM and
delphinidin found in aortas from ERa WT is completely abolished
when ERa is deleted. Interestingly, both compounds elicit
contraction in endothelium-denuded arteries taken from ERa
deficient mice suggesting that the molecular targets of the two
compounds on the smooth muscle are different to ERa (data not
shown). Moreover, the ability of the two compounds to enhance
the rapid release of NO (10 min) from cultured endothelial cells
associated with phosphorylation of Src, ERK1/2, eNOS and
caveolin-1 is blunted after silencing ERa either by Fulvestrant or
siRNA. Finally, the capacity of Provinols
TM and delphinidin to
increase NO in mouse aortic endothelial cells was not only
abolished in the presence of Fulvestrant and most likely when these
cells were taken from ERa deficient mice. Altogether, these data
demonstrate the direct link between the ability of Provinols
TM and
delphinidin to stimulate NO pathways leading to endothelial NO
production through ERa activation. Very recently, it has been
reported that the stilbene, resveratrol, rapidly activates MAPK
signalling through ER localized in a ‘‘signalosome complex’’ at the
plasma membrane and that may couple to G proteins, activate
MEK1 and cause the release of Ca
2+ accounting for NO release in
endothelial cells [23]. However, the exact nature of the receptor
isoform involved, ERa or ERb, has not been directly assessed in
their study although it is now well accepted that ERa is necessary
in the response of E2 on endothelial NO production [2].
In the present study, direct interaction of delphindin with ERa
excluding the implication of other factors is demonstrated by the
capacity of this compound to exert 73% of specific inhibition
against E2 on ERa. Furthermore, we perform a docking study of
delphinidin on ERa. The predicted binding mode of the ligand-
binding domain on ERa is relatively similar to that observed in the
X-ray structure of the ERa with E2.
Altogether, these data provide evidence that red wine
polyphenols and delphinidin in particular, through direct
interaction with ERa, activate molecular pathways including
Src, ERK1/2, eNOS, leading to endothelial NO production,
accounting for vasorelaxation.
Finally, we demonstrate that the ability of oral administration of
Provinols
TM to decrease contraction to serotonin in the presence
of functional endothelium and to improve endothelium-dependent
relaxation in aorta from ERa WT mice in association with
increased NO production and reduced superoxide anions in
mesenteric arteries are completely blunted in ERa deficient mice.
These data strongly suggest that ERa triggers the in vivo effects of
Provinols
TM and demonstrate for the first time the physiological
relevance of this receptor. One can advance the hypothesis that
ERa might by the or one of the molecular target(s) triggering the
beneficial effects of dietary supplementation of Provinols
TM on
obesity-associated alterations with respect to metabolic distur-
bances and cardiovascular functions recently reported in Zucker
fatty (ZF) rats [24]. Further studies should be conducted in order
Figure 4. Binding assay and docking show direct interaction between delphinidin and ERa activator site. Binding mode of 17-b
estradiol (E2) (panel A, X-ray structure) and delphinidin (panel B, docking model) to the ligand-binding domain of the ERa (1a52 PDB entry). The
receptor backbone is displayed by solid ribbons. Ligand-contacting side chains are displayed by white ball and sticks. Carbon atoms of receptor-
bound E2 and delphinidin are in yellow and green, respectively. In panel C, the ligand-receptor interactions for both compounds are encoded by an
interaction fingerprint converting into a 7 bit string the interaction of the ligand with each residue of the binding site using the following color-
coding: blue, apolar contact; green: aromatic interaction; red: hydrogen-bond. Eventually, D represents results of a binding assay of delphinidin on
ERa.E 2 was used as control agonist for ERa and delphinidin was used at concentration exerting endothelial effects shown before (10
22 g/L).
doi:10.1371/journal.pone.0008554.g004
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cardiovascular effects induced by red wine polyphenols including
ERb or cyclooxygenase pathways.
The findings that vascular protection induced by red wine
polyphenols, and in particular by delphinidin, requires ERa
activation is a major breakthrough in understanding the
therapeutic potential of polyphenols in cardiovascular pathologies.
These properties of red wine might explain the prevention of
ischemic heart disease [24,25], stroke [10] and metabolic diseases
[24], in different experimental models.
Methods
Provinols
TM was obtained from Socie ´te ´ Franc ¸aise des Distiller-
ies (Vallon Pont d’Arc, France) and delphinidin was purchased
from Extrasynthe `se (Genay, France). The university of Angers
ethical committee approved the present protocol. All animal
studies were carried out using approved institutional protocols and
were conformed the Guide for the Care and Use of Laboratory
Animals published by US National Institutes of Health (NIH
Publication No. 85–23, revised 1996). Methods for vascular
reactivity performed in mice [26,27] and endothelial cells
extraction and culture were set up as previously described [19].
Methods for RNA interference and transient transfection to silence
ERa were adapted from Agouni et al. [26]. NO and O2
2 spin
trapping and electronic paramagnetic resonance (EPR) studies and
Western blotting were conducted as previously described [26].
Binding assay was performed by CEREP (Paris, France) using
fluorescence polarization methods in human recombinant Sf9.
Delphinidin was docked on ERa using default settings of the
GOLD4.0 program [28]. Additional details of the methods used
are provided in the Supplemental Data file (Methods S1).
Figure 5. Involvement of ERa in vascular effects induced by an oral treatment with Provinols
TM. Concentration-effect curves to
increasing concentrations of serotonin (5-HT) in aortas, with endothelium, from ERa Wild Type (WT) (A) or Knock-Out (KO) (B) mice treated either with
control diet (open circles) or diet containing Provinols
TM for 2 weeks at 20 mg/kg/day (filled circles, ***P,0.001, n=6). Concentration-effect curves to
increasing concentrations of acetylcholine (Ach) in aortas with endothelium, pre-contracted at 80% of the maximal contraction with U46619 from ERa
WT (C) or KO (D) mice treated either with control diet (open circles) or diet containing Provinols
TM for 2 weeks at 20 mg/kg/day (filled circles)
(*P,0.05, n=6). Quantification of NO (E) and O2
2 production (F) in mesenteric arteries from ERa WT or KO mice receiving either standard diet or diet
containing Provinols
TM (*P,0.05 vs control diet; #P,0.05 KO vs WT; n=5).
doi:10.1371/journal.pone.0008554.g005
ERa and Red Wine Polyphenols
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Methods S1
Found at: doi:10.1371/journal.pone.0008554.s001 (0.04 MB
DOC)
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